CN101257889A - 托吡酯的儿科制剂 - Google Patents

托吡酯的儿科制剂 Download PDF

Info

Publication number
CN101257889A
CN101257889A CNA2006800178845A CN200680017884A CN101257889A CN 101257889 A CN101257889 A CN 101257889A CN A2006800178845 A CNA2006800178845 A CN A2006800178845A CN 200680017884 A CN200680017884 A CN 200680017884A CN 101257889 A CN101257889 A CN 101257889A
Authority
CN
China
Prior art keywords
composition
topiramate
composition according
pharmaceutically acceptable
organic solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800178845A
Other languages
English (en)
Chinese (zh)
Inventor
M·K·J·弗兰科伊斯
W·M·A·C·德里斯
R·C·A·埃姆布雷克茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35045349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101257889(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN101257889A publication Critical patent/CN101257889A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CNA2006800178845A 2005-05-25 2006-05-23 托吡酯的儿科制剂 Pending CN101257889A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05104491 2005-05-25
EP05104491.5 2005-05-25
US60/690,391 2005-06-14

Publications (1)

Publication Number Publication Date
CN101257889A true CN101257889A (zh) 2008-09-03

Family

ID=35045349

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800178845A Pending CN101257889A (zh) 2005-05-25 2006-05-23 托吡酯的儿科制剂

Country Status (12)

Country Link
US (1) US20060270611A1 (cg-RX-API-DMAC7.html)
EP (1) EP1888030A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008542237A (cg-RX-API-DMAC7.html)
CN (1) CN101257889A (cg-RX-API-DMAC7.html)
AR (1) AR053737A1 (cg-RX-API-DMAC7.html)
AU (1) AU2006251213A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0610210A2 (cg-RX-API-DMAC7.html)
CA (1) CA2609719A1 (cg-RX-API-DMAC7.html)
MX (1) MX2007014713A (cg-RX-API-DMAC7.html)
RU (1) RU2007148444A (cg-RX-API-DMAC7.html)
TW (1) TW200716202A (cg-RX-API-DMAC7.html)
WO (1) WO2006125774A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104188920A (zh) * 2014-07-28 2014-12-10 安徽省逸欣铭医药科技有限公司 托吡酯颗粒剂及其制备方法
CN117159458A (zh) * 2022-05-27 2023-12-05 北京万全德众医药生物技术有限公司 托吡酯口服溶液及其制备方法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
WO2011141490A1 (en) 2010-05-10 2011-11-17 Euro-Celtique S.A. Combination of active loaded granules with additional actives
MX340188B (es) 2010-05-10 2016-06-30 Euro-Celtique S A * Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
CA2881144A1 (en) * 2012-11-09 2014-05-09 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
JP6232135B2 (ja) 2013-11-13 2017-11-15 ユーロ−セルティーク エス.エイ. 疼痛およびオピオイドによる腸機能障害症候群の治療のためのヒドロモルホンおよびナロキソン
KR102615486B1 (ko) * 2015-08-24 2023-12-19 조게닉스 인터내셔널 리미티드 펜플루라민을 사용하여 레녹스-가스토 증후군을 치료하는 방법
WO2017085687A1 (en) 2015-11-20 2017-05-26 West-Ward Pharmaceuticals International Limited Stable formulation of phenobarbital sodium injection
DK3800177T3 (da) 2015-12-22 2025-03-31 Zogenix International Ltd Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
US10689324B2 (en) 2015-12-22 2020-06-23 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
RU2021106383A (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
WO2019186515A1 (en) * 2018-03-30 2019-10-03 Ftf Pharma Private Limited Liquid pharmaceutical compositions of antiepileptic drugs
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US10517841B1 (en) 2018-06-14 2019-12-31 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
WO2020053662A2 (en) * 2018-09-13 2020-03-19 Ftf Pharma Private Limited Non-aqueous solutions for oral dosage
WO2020105005A1 (en) 2018-11-19 2020-05-28 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
WO2020104837A1 (en) 2018-11-21 2020-05-28 Rosemont Pharmaceuticals Limited Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
US20210169844A1 (en) 2019-12-10 2021-06-10 Tulex Pharmaceuticals Inc. Compositions and methods for treating epilepsy, seizures and other conditions
GB2594242A (en) * 2020-04-14 2021-10-27 Syri Ltd A stable and ready to administer liquid pharmaceutical composition of topiramate
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20250120951A1 (en) * 2021-07-30 2025-04-17 Epygenix Therapeutics, Inc. Clemizole formulation
US12109188B1 (en) 2023-03-24 2024-10-08 Tap Pharmaceuticals Ag Liquid pharmaceutical formulations of topiramate
US12290504B2 (en) * 2023-04-11 2025-05-06 Tap Pharmaceuticals Ag Aqueous formulations of topiramate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
AU651244B2 (en) * 1991-09-19 1994-07-14 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
JP2004331502A (ja) * 2001-06-18 2004-11-25 Ortho Mcneil Pharmaceut Inc 視神経細胞保護剤
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
EP1684713A1 (en) * 2003-11-14 2006-08-02 ALZA Corporation Controlled release of topirimate in liquid dosage forms

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104188920A (zh) * 2014-07-28 2014-12-10 安徽省逸欣铭医药科技有限公司 托吡酯颗粒剂及其制备方法
CN117159458A (zh) * 2022-05-27 2023-12-05 北京万全德众医药生物技术有限公司 托吡酯口服溶液及其制备方法

Also Published As

Publication number Publication date
JP2008542237A (ja) 2008-11-27
US20060270611A1 (en) 2006-11-30
CA2609719A1 (en) 2006-11-30
EP1888030A1 (en) 2008-02-20
RU2007148444A (ru) 2009-06-27
MX2007014713A (es) 2008-02-14
AU2006251213A1 (en) 2006-11-30
WO2006125774A1 (en) 2006-11-30
BRPI0610210A2 (pt) 2010-06-01
AR053737A1 (es) 2007-05-16
TW200716202A (en) 2007-05-01

Similar Documents

Publication Publication Date Title
US20060270611A1 (en) Pediatric formulation of topiramate
US12611377B2 (en) Pharmaceutical composition comprising an androgen receptor inhibitor
EP2680813B1 (en) Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer
US8703156B2 (en) Liquid formulation for deferiprone with palatable taste
JP7213882B2 (ja) ケトン食療法に適合したフェンフルラミン製剤
US9326935B2 (en) Atomoxetine solution
US11426413B2 (en) Oral liquid compositions including chlorpromazine
GB2594242A (en) A stable and ready to administer liquid pharmaceutical composition of topiramate
US12576026B2 (en) Formulations of nebivolol
AU2002350081B2 (en) Ribavirin syrup formulations
EP1176982B1 (en) Prucalopride oral solution
EP2926816A1 (en) Pharmaceutical composition comprising desloratadine and prednisolone and use thereof
JP2016526553A (ja) フェキソフェナジンを含む経口投与用液体医薬組成物
US20220160698A1 (en) Pharmaceutical oral liquid solution of ivacaftor
WO2024116198A1 (en) Oral liquid formulation of empagliflozin or its pharmaceutically acceptable salt thereof
WO2019162756A2 (en) Liquid pharmaceutical compositions of anticancer drugs
HK1120413A (en) Pediatric formulation of topiramate
US12508315B2 (en) Use of vitamin E TPGS as a taste masking agent for bitter drugs
KR20080016630A (ko) 소아용 토피라메이트 제형
WO2024144482A1 (en) Pharmaceutical oral suspension compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients
CA3243492A1 (en) LIQUID PHARMACEUTICAL FORMULATION OF OMEPRAZOLE OR ESOMEPRAZOLE
HK1152871B (en) Liquid formulation for deferiprone with palatable taste
SG190579A1 (en) Liquid formulation for deferiprone with palatable taste

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1120413

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080903

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1120413

Country of ref document: HK